Journal profile · Hematology
American Journal of Hematology
ISSN 0361-8609 · eISSN 1096-8652 · Wiley-Liss Inc. · UNITED STATES · Monthly · Founded 1976
American Journal of Hematology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 9.37; hybrid open access; APC about USD 5,450; median 66 days to acceptance (93 articles, last 24 months); community-reported acceptance: fairly easy; 405 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
American Journal of Hematology is published by Wiley-Liss Inc. and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Hemoglobinopathies and Related Disorders, Acute Myeloid Leukemia Research and Chronic Lymphocytic Leukemia Research, together about 26.6% of its articles. Its main subfields are Hematology and Genetics. (generated from OpenAlex topic counts and CAS ranking data)
The American Journal of Hematology provides broad coverage of experimental and clinical features of blood diseases in humans and in animal models of human disease. The journal publishes original contributions in non-malignant and malignant hematological diseases including clinical and basic studies in hemostasis and thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports describing novel therapeutic approaches to diagnosis and treatment of hematological diseases are welcomed and encouraged. The journal includes regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, letters and correspondence.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief Carlo BrugnaraPublisher website
Editorial board by country: none in mainland China; most named Greece 2, United States 1, United Kingdom 1, France 1, Italy 1 (6 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Hemoglobinopathies and Related DisordersMedicine10.5%
- Acute Myeloid Leukemia ResearchMedicine9.3%
- Chronic Lymphocytic Leukemia ResearchMedicine6.8%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine6.4%
- Lymphoma Diagnosis and TreatmentMedicine6.1%
- Platelet Disorders and TreatmentsMedicine5.8%
- Blood groups and transfusionMedicine5.7%
- Iron Metabolism and DisordersMedicine5.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCASCAB AbstractsCurrent ContentsPublisher website
Other: ProQuest
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 9.37LetPub ·
- Impact factor (publisher)
- 9.4Publisher website ·
- Impact factor (publisher) 2025
- 9.4Publisher website ·
- CiteScore 2026-06
- 14.9LetPub ·
- CiteScore (publisher)
- 14.9Publisher website ·
- CiteScore (publisher) 2025
- 14.9Publisher website ·
- SJR 2026-06
- 3.49LetPub ·
- SNIP 2026-06
- 3.12LetPub ·
- h-index
- 92LetPub ·
- h-index
- 174OpenAlex ·
- i10-index
- 7,212OpenAlex ·
- 2-year mean citedness
- 5.61OpenAlex ·
- Self-citation rate
- 3.2%LetPub ·
- Share of gold OA articles
- 46.03%LetPub ·
Volume
- Articles per year
- 158LetPub ·
- Articles per year (publisher) 2025
- 357Publisher website ·
- Downloads per year (publisher) 2025
- 3,066,629Publisher website ·
Articles by year OpenAlex count · 13,919 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 341 | 223 | 184 |
| 2025 | 405 | 320 | 1,848 |
| 2024 | 403 | 363 | 4,412 |
| 2023 | 389 | 356 | 6,458 |
| 2022 | 373 | 220 | 7,668 |
| 2021 | 378 | 306 | 9,603 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
66 daysMedian, submission to acceptance · P25–P75 35 days – 115 days
- Acceptance to online
- median 14 days (94 articles)
- Submission to online
- median 85 days
- Sample
- 93 articles with submission and acceptance dates (802 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–6 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 17%Publisher website ·
- Acceptance rate (publisher) 2025
- 17%Publisher website ·
- Submission to first decision
- 4 daysPublisher website ·
- Submission to first decision 2025
- 4 daysPublisher website ·
- Submission to acceptance 2025
- 65 daysPublisher website ·
- Acceptance to publication 2025
- 17 daysPublisher website ·
- Peer review
- Single-anonymous peer reviewPublisher website · model-extracted
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 5,450 / EUR 4,550 / GBP 3,630 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Reference style
- Author–date
- First submission
- Free format: the journal's layout is not required
Article types accepted3, with length limits
- commentaryCommentaries are usually invited but may be submitted independently after consultation with the Editor-in-Chief. Please limit the text to 2,500 words and fewer …main text ≤ 2,500 words · references ≤ 10
- correspondencel observations may also be appropriate. Correspondence to the Editor should be no more 1,500 words, no more than 20 references and 3 tables/figures. No abstramain text ≤ 1,500 words · references ≤ 20
- reviewhat remain controversial or unanswered. Reviews should normally comprise less than 6,000 words, contain an unstructured abstract of 100 words or less, andmain text ≤ 6,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Artificial Intelligence Generated Content
Artificial Intelligence Generated Content (AIGC) tools — such as ChatGPT and others based on large language models (LLMs) — cannot be considered capable of initiating an original piece of research without direction by human authors. They also cannot be accountable for a published work or for a research design, which is a generally held requirement of authorship, nor do they have legal standing or …
Source ↗Publisher website ·- Authorship
Originality policy: manuscripts must be submitted solely to this journal and not published elsewhere. Model summary
All manuscripts submitted to the American Journal of Hematology must be submitted solely to this journal. Submissions may not have been published in any part or form in another publication of any type, professional or lay, or become the property of another publisher.
Source ↗Publisher website ·- Conflicts of interest Disclosure statement
All authors must disclose any affiliations that they consider to be relevant and important with any organization that to any author's knowledge has a direct interest, particularly a financial interest, in the subject matter discussed. Such affiliations include, but are not limited to, employment by an industrial entity, ownership of stock, membership on a standing advisory council or committee, a …
Source ↗Publisher website ·- Data availability Data Sharing and Data Availability
Data sharing expected; data availability statement required. Model summary
This journal expects data sharing. Review Wiley’s Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission.
Source ↗Publisher website ·- License & copyright For authors signing the copyright transfer agreement
Permission policy: reproduced/adapted material must be acknowledged and permission obtained by the author. Model summary
If the open access option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:
Source ↗Publisher website ·- Open access For authors choosing Open Access
If the open access option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Source ↗Publisher website ·- Peer review
Preferred reviewers policy: provide three preferred reviewers from other institutions. Model summary
When submitting the manuscript online, provide the names, affiliations, and email addresses of three preferred reviewers at institutions other than those of the authors.
Source ↗Publisher website ·- Trial registration / reporting guidelines
Clinical trial registration/protocol policy: prospective clinical trials must include final protocol and SAP. Model summary
AJH welcomes submission of prospective clinical trials in hematology. For all prospective clinical trials, authors should include the final study protocol with a detailed list of protocol amendments, as well as the final statistical analysis plan (SAP) with a detailed list of SAP amendments (if the trial has a SAP separate from the protocol) among the files submitted during initial submission.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Liss Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1976
- ISSN
- 0361-8609
- Electronic ISSN
- 1096-8652
- Latest issue on the website
- Volume 101, Issue 10 (October 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
FAQ
Frequently asked questions about American Journal of Hematology
What CAS zone is American Journal of Hematology in?
In the 2025 upgraded edition of the CAS Journal Ranking, American Journal of Hematology is in Zone 1 of Medicine, and in Zone 2 of the minor category Hematology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of American Journal of Hematology?
The latest impact factor listed by LetPub is 9.37; CiteScore 14.9, h-index 174.
How long does peer review take at American Journal of Hematology?
Based on the dates recorded on 93 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 66 days (interquartile range 35–115 days); authors report an average review time of 3–6 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 17% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of American Journal of Hematology?
According to the journal's author guidelines: Reference style: Author–date; First submission: Free format: the journal's layout is not required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of American Journal of Hematology based?
Of the 6 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Greece (2), United States (1) and United Kingdom (1). Counted from the institutions listed on the board page; for reference only.
Which databases index American Journal of Hematology?
According to LetPub and DOAJ records, American Journal of Hematology is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase, CAS, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is American Journal of Hematology open access, and what is the APC?
American Journal of Hematology is a hybrid journal. For open-access publication: APC about USD 5,450.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .